Half-Year 2022 Financial and Clinical Trials Update

Gazyva (obinutuzumab) Immunology development program Indication Phase/study # of patients Design Primary endpoint Status CT Identifier In collaboration with Biogen IV=Intravenous • Systemic lupus erythematosus (SLE) Phase III ALLEGORY N=200 . . ARM A: Gazyva 1000mg IV on Day 1 and Weeks 2, 24 and 26. ARM B: Placebo IV Percentage of participants who achieve Systemic Lupus Erythematosus Responder Index (SRI) at week 52 • FPI Q4 2021 NCT04963296 Roche 114 Immunology

View entire presentation